Human occupation of northern India spans the Toba super-eruption ~74,000 years ago.

India is located at a critical geographic crossroads for understanding the dispersal of Homo sapiens out of Africa and into Asia and Oceania. Here we report evidence for long-term human occupation, spanning the last ~80 thousand years, at the site of Dhaba in the Middle Son River Valley of Central India. An unchanging stone tool industry is found at Dhaba spanning the Toba eruption of ~74 ka (i.e., the Youngest Toba Tuff, YTT) bracketed between ages of 79.6 ± 3.2 and 65.2 ± 3.1 ka, with the introduction of microlithic technology ~48 ka. The lithic industry from Dhaba strongly resembles stone tool assemblages from the African Middle Stone Age (MSA) and Arabia, and the earliest artefacts from Australia, suggesting that it is likely the product of Homo sapiens as they dispersed eastward out of Africa.

P-gp modulatory acetyl-11-keto-ß-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel.

In spite of being a very potent and promising drug against many types of cancer, docetaxel suffers the disadvantage of low solubility and poor bioavailability rendering it unsuitable for oral administration. Also, the available marketed formulation for intravenous administration has its inherent drawbacks owing to the presence of polysorbate 80. Here, we exploited the anticancer and P-gp inhibitory potential of naturally occurring frankincense oil to fabricate a stable docetaxel loaded nanoemulsified carrier system for oral delivery. The nanoemulsion possessing desirable particle size (122±12nm), polydispersity (0.086±0.007) and zeta potential (-29.8±2.1mV) was stable against all type of physical stresses and simulated physiological conditions tested. The formulation showed higher uptake in Caco-2 cells and inhibited P-gp transporter significantly (P<0.05). In MDA-MB-231 cells, it showed less IC50, arrested cells in G2-M phase and exhibited higher degree of apoptosis than marketed formulation Taxotere®. The 182.58±4.16% increment in relative oral bioavailability led to higher in vivo anti-proliferative activity manifesting 19% more inhibition than Taxotere®. Conclusively, it is revealed that the developed nanoemulsion will be a propitious approach towards alternative docetaxel therapy.

Receptor conversion in carcinoma breast metastatic to the bone marrow.

Breast cancer is the first in the incidence of malignancies among women. The documented frequency of osseous metastasis from breast cancer is about 12.8 %. Although breast cancer cells have been documented in the bone marrow in autopsy, haematological manifestations due to metastatic disease to the marrow is rare. The prognosis of these cases is dismal and improper management worsen the condition further. IHC for ER, PR & Her 2/neu status plays a vital role in ascertaining the treatment protocol both in primary tumors as well as metastatic or recurrent tumors. Receptor conversion has been documented in metastatic and recurrent cases. We report a case of 65 year female with a history of ER, PR positive and Her 2/neu negative carcinoma breast 3½ years back, presented with anemia and low back ache diagnosed as metastatic breast carcinoma to bone marrow with receptor conversion.

Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.

Tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent with cancer cell-selective cell death inducing effect. However, the major limitation in the usage of TRAIL as a chemotherapeutic agent is the development of TRAIL resistance in many cancer types including myeloid leukemia. In this study, we report for the first time that Medicarpin (Med), a naturally occurring phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis. Combination of Med and TRAIL induced significantly higher apoptosis compared with that of the individual treatments of either agent alone through activation of both the extrinsic and the intrinsic cell death pathways characterized by the activation of caspases 8, 9, 3, and 7. Med treatment downregulated antiapoptotic proteins (Survivin, Bcl2, Bcl-xL, XIAP, and c-FLIP), upregulated pro-apoptotic proteins (Bax, Cytochrome C, Smac/Diablo, Bid, truncated Bid (tBid), p-eIF2α, Bip, and CHOP (CCAAT-enhancer binding protein homologous protein)), induced G2/M cell-cycle arrest, and increased the expression of the functional TRAIL receptor DR5 through activation of the ROS-JNK-CHOP pathway. Gain and loss of function studies clearly indicated that DR5 expression was critical for Med-induced TRAIL sensitization. The Med-induced TRAIL sensitization did not involve the NFkB signaling pathway or redistribution of DR5 in lipid rafts. The concomitant treatment with Med and TRAIL showed robust apoptotic effects in primary myeloid leukemia cells but had no toxic effects in primary human peripheral blood mononuclear cells (PBMCs). In conclusion, our results suggest that Med sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the upregulation of DR5 through activation of the ROS-JNK-CHOP pathway.

A novel therapeutic approach with Caviunin-based isoflavonoid that en routes bone marrow cells to bone formation via BMP2/Wnt-ß-catenin signaling.

Recently, we reported that extract of Dalbergia sissoo made from leaves and pods have antiresorptive and bone-forming effects. The positive skeletal effect attributed because of active molecules present in the extract of Dalbergia sissoo. Caviunin 7-O-[ß-D-apiofuranosyl-(1-6)-ß-D-glucopyranoside] (CAFG), a novel isoflavonoid show higher percentage present in the extract. Here, we show the osteogenic potential of CAFG as an alternative for anabolic therapy for the treatment of osteoporosis by stimulating bone morphogenetic protein 2 (BMP2) and Wnt/ß-catenin mechanism. CAFG supplementation improved trabecular micro-architecture of the long bones, increased biomechanical strength parameters of the vertebra and femur and decreased bone turnover markers better than genistein. Oral administration of CAFG to osteopenic ovariectomized mice increased osteoprogenitor cells in the bone marrow and increased the expression of osteogenic genes in femur and show new bone formation without uterine hyperplasia. CAFG increased mRNA expression of osteoprotegerin in bone and inhibited osteoclast activation by inhibiting the expression of skeletal osteoclastogenic genes. CAFG is also an effective accelerant for chondrogenesis and has stimulatory effect on the repair of cortical bone after drill-hole injury at the tissue, cell and gene level in mouse femur. At cellular levels, CAFG stimulated osteoblast proliferation, survival and differentiation. Signal transduction inhibitors in osteoblast demonstrated involvement of p-38 mitogen-activated protein kinase pathway stimulated by BMP2 to initiate Wnt/ß-catenin signaling to reduce phosphorylation of GSK3-ß and subsequent nuclear accumulation of ß-catenin. Osteogenic effects were abrogated by Dkk1, Wnt-receptor blocker and FH535, inhibitor of TCF-complex by reduction in ß-catenin levels. CAFG modulated MSC responsiveness to BMP2, which promoted osteoblast differentiation via Wnt/ß-catenin mechanism. CAFG at 1 mg/kg(/)day dose in ovariectomy mice (human dose ∼0.081 mg/kg) led to enhanced bone formation, reduced bone resorption and bone turnover better than well-known phytoestrogen genistein. Owing to CAFG's inherent properties for bone, it could be positioned as a potential drug, food supplement, for postmenopausal osteoporosis and fracture repair.

Birth of the first mithun ( Bos frontalis) calf through artificial insemination.

The study describes the standardization of a suitable semen cryopreservation protocol for the first time in mithun (Bos frontalis) and birth of the first mithun calf through artificial insemination. The semen samples were collected from adult bulls through the rectal massage method and cryopreserved in liquid nitrogen using tris-egg yolk-glycerol diluent. The diluted semen samples were packaged in 0.50 ml straws and kept at 5°C for 4 h for equilibration. Following the equilibration, the straws were frozen into liquid nitrogen vapour for 10 min and then plunged into liquid nitrogen for storage. It was observed that the progressive motility (%) decreased significantly (P < 0.01) in cryopreserved semen (43.3 ± 4.1) compared with fresh samples (76.6 ± 3.3). The percentages of live spermatozoa (P < 0.01) and spermatozoa with intact acrosome (P < 0.05) also decreased significantly in cryopreserved semen (54.0 ± 3.3 and 64.6 ± 5.3) compared with fresh samples (79.3 ± 2.6 and 85.3 ± 1.8). Simultaneously, the total morphological abnormality (%) was found to be significantly (P < 0.01) higher in cryopreserved samples (15.46 ± 2.68) than in fresh semen (3.85 ± 0.63). A total of three mithun cows were inseminated using the cryopreserved semen. All the cows conceived following insemination and gave birth to healthy calves. The study revealed that mithun semen can be cryopreserved efficiently using tris-egg yolk-glycerol diluent, which can be further used for artificial insemination.

Development and validation of a sensitive radioimmunoassay procedure for estimating FSH in mithun (Bos frontalis) plasma.

The present study was designed to develop and validate a simple and sensitive radioimmunoassay (RIA) procedure to estimate FSH in mithun (Bosfrontalis) plasma. The assay was carried out in 100 [L of mithun plasma. The bovine FSH standards (10 to 5000 pg/100 microL/tube) in hormone-free plasma were used in the assay. The sensitivity of the assay was 20 pg/100 microL/tube, which corresponded to 0.20 ng/mL plasma. The 50% relative binding sensitivity of the assay was 80 pg/100 microL/tube, which corresponded to 0.80 ng/mL plasma. The intra- and inter-assay coefficients of variation were 4.6% and 12.4%, respectively. The biological validation of the assay was carried out in plasma samples that were collected during different stages of the estrous cycle. In the entire estrous cycle, plasma FSH concentration (p < 0.01) attained two peaks (on day 3 to 4 before estrus 5.1 +/- 0.3 ng/mL and on the day of estrus 6.9 +/- 0.2 ng/mL). FSH concentration remained at basal level (1.3 +/- 0.1 to 1.6 +/- 0.2 ng/mL) during day 4 to 16 of the estrous cycle. The concentration of plasma FSH was found to be significantly (p < 0.05) higher (4.9 +/- 0.3 to 6.8 +/- 0.5 ng/mL) until 48 h following the estrus onset. In conclusion, the RIA procedure that was developed in the current study is sufficiently reliable and sensitive to estimate different physiological levels of FSH in mithun plasma.

Endotoxin induces luteal cell apoptosis through the mitochondrial pathway.

The effect of endotoxin (lipopolysacharide, LPS) exposure on luteal cells was studied using an in vitro cell culture system. Buffalo luteal cells were isolated from corpora lutea of the late luteal phase (days 14-16 post estrus) and exposed to various LPS doses (5, 10 and 100 microg/ml) for different time periods (6, 12, 18 or 24 h). The cultured cells were subsequently evaluated for oxidative stress (super oxide, nitric oxide, inducible nitric oxide synthase activity, reduced glutathione depletion and lipid peroxidation) and apoptotic markers (mitochondrial membrane potential, DNA fragmentation, apoptotic cells and cell viability). LPS exposure significantly increased the production of super oxide (P<0.05) and nitric oxide (P<0.01) and increased inducible nitric oxide synthase activity (P<0.01). LPS exposure further depleted reduced glutathione (P<0.05) levels and induced lipid peroxidation (P<0.05). LPS exposure also induced the loss of mitochondrial membrane potential (P<0.05), increased DNA fragmentation (P<0.01) and apoptosis (P<0.01) and decreased cell viability (P<0.01). LPS mediated apoptotic pathway in luteal cells was further characterized using a selected LPS dose (10 microg/ml). It was observed that LPS exposure induced mitochondrial translocation of proapoptotic protein Bax, increased the total Bad expression and down regulated the expression of antiapoptotic proteins Bcl2 and BclXL. LPS exposure further induced cytochrome c release and increased Caspase-9 (P<0.01) and Caspase-3 (P<0.01) activities. LPS exposure also inhibited luteal progesterone secretion (P<0.01). It was evident that the LPS mediated apoptotic effects could be prevented by the coincubation of luteal cells with mitochondrial permeability transition pore blocker Cyclosporine A, inducible nitric oxide synthase inhibitor N-[3-(aminomethyl)benzyl]acetamidine and oxidative stress scavenger N-acetyl cysteine. Our study clearly indicates that LPS induces oxidative stress mediated apoptosis in luteal cells through the mitochondrial pathway.

Preservation of mithun (Bos frontalis) semen at refrigeration temperature.

The objective of the present study was to investigate the possibility of preserving mithun (Bos frontalis) spermatozoa at refrigeration temperature using tris-egg yolk diluent. Semen samples were collected from four adult mithun bulls through rectal massage method. Good quality semen samples (n=30) were preserved at 4 degrees C using tris-egg yolk diluent for 72 h. Progressive motility, live spermatozoa count and morphological abnormalities were evaluated every 12 h until 72 h of preservation. The colour, consistency and mass activity of fresh semen samples were found to be creamy white, medium and 3+ to 4+ (5+ scale), respectively. The average (mean+/-S.E.) volume (ml), pH and spermatozoa concentration (10(6) ml(-1)) of fresh semen samples were found to be 0.6+/-0.01, 6.8+/-0.03 and 425+/-48, respectively. Progressive motility and live spermatozoa count were found to be less than 30% (P<0.01) after 48 h of storage. Head (P<0.05), midpiece (P<0.05), tail (P<0.01) and total (P<0.01) abnormalities were found to be increased significantly over the time of storage. It was observed that progressive motility and live spermatozoa count remained above 30% and 40%, respectively, until 36 h of storage. Simultaneously the percentage of morphologically abnormal spermatozoa was found to be significantly low until 36 h of storage. The results indicate that it is possible to preserve mithun spermatozoa at refrigeration temperature in tris-egg yolk diluent, which can be further used for artificial insemination within 36 h of storage.

Secretion patterns of luteinising hormone, follicle-stimulating hormone and 17beta-oestradiol during oestrus and the mid-luteal phase of the oestrous cycle in mithun (Bos frontalis).

The present study reports the pulsatile secretion of gonadotrophins and 17beta-oestradiol (OE2) on the day of oestrus and at the mid-luteal phase of the oestrous cycle in mithun (Bos frontalis). The frequency of luteinising hormone (LH) and follicle-stimulating hormone (FSH) pulses was found to be greater (P < 0.05) on the day of oestrus than at the mid-luteal phase. In contrast, the amplitude of the LH and FSH pulses was greater (P < 0.01) at the mid-luteal phase than on the day of oestrus. A synchronised (P < 0.01) LH and FSH secretion pattern was found only at the mid-luteal phase. A pulsatile secretion pattern for OE2 in the peripheral circulation was evident for both phases of the oestrous cycle. The frequency of the OE2 pulses did not differ significantly in different phases of the oestrous cycle. In contrast, the amplitude of the OE2 pulses and the basal OE2 concentration were found to be greater (P < 0.01) at the mid-luteal phase than on the day of oestrus. A synchronised (P < 0.01) LH and OE2 secretion pattern was observed in both phases of the oestrous cycle. In contrast, a synchronised (P < 0.05) FSH and OE2 secretion pattern was found only on the day of oestrus. In conclusion, a different pattern of LH and FSH secretion was observed in both phases of the oestrous cycle, mainly on the day of oestrus, which indicates a differential regulatory mechanism of LH and FSH release. In addition, as in cattle, OE2 exerts a positive feedback on LH and FSH release on the day of oestrus and on LH release at the mid-luteal phase of the oestrous cycle in mithun. Also, as in cattle, the greater basal plasma OE2 concentration and increased amplitude of OE2 pulses exert a negative feedback on FSH release at the mid-luteal phase of the oestrous cycle.

Role of LH and prostaglandin F2alpha on the development and regression of corpus luteum in mithun (Bos frontalis) estrous cycle.

The present investigation was designed to study the role of LH and prostaglandin F2alpha (PGF2alpha) on the development and regression of corpus luteum (CL) in the mithun estrous cycle. Blood samples were collected from jugular vein and PGF2alpha secretion was evaluated on the basis of peripheral 15-keto-13,14-dihydro-PGF2alpha (PGFM) concentration. The daily variations in plasma LH, PGFM, and progesterone (P4) concentrations throughout the estrous cycle were monitored in morning and evening blood samples. The variations in plasma LH, PGFM, and P4 concentrations during the early luteal phase were monitored in blood samples that were collected every 2 h until 120 h following the onset of estrus (Day 0). The pulsatile secretion patterns of plasma LH, PGFM and P4 during estrus (Day 1), mid-diestrus (Day 10), and luteolysis (Day 14) were assessed in blood samples that were collected every 15 min for 6h. In the estrous cycle, P4 concentration increased above basal level on day 6-7, peaked on day 10-12 and declined thereafter. Following estrus, a significant (P<0.01) gradual increase in P4 concentration was observed. LH concentration was found to be significantly (P<0.01) greater around estrus and it declined gradually (P<0.01) following estrus. In the estrous cycle, PGFM concentration increased above basal level on day 9-11, peaked on day 16-17, and declined thereafter. The frequency of LH pulses and basal LH concentration were found to be significantly (P<0.01) greater on day 1, but significantly (P<0.01) greater amplitude of LH pulses was found on day 10 and 14. The frequency of P4 and PGFM pulses was found to be significantly (P<0.01) greater on day 1. In contrast, the amplitude of P4 and PGFM pulses and basal P4 and PGFM concentrations were found to be significantly (P<0.01) greater on day 10 and 14. The results indicate that probably the early stages of CL development continued until day 5-6 of the estrous cycle and a fully functional CL existed approximately at the mid estrous cycle. Luteolysis probably started since day 11-13 of the cycle and completed before the onset of the next estrus. The elevated basal LH concentration along with frequent low amplitude LH pulses were probably required for the early stages of CL development. In contrast, the high amplitude LH pulses of lower frequency during the mid estrous cycle were either sufficient or not required for maintaining the luteal function. Whereas, PGF2alpha pulses of greater amplitude and elevated basal PGF2alpha concentration during the mid and late estrous cycle were probably responsible for luteolysis.

Changes in plasma concentrations of LH, FSH, estradiol 17-beta and progesterone during oestrus in mithun (Bos frontalis).

The objective of the present study was to establish the changes in plasma concentrations of LH, FSH, estradiol 17-beta (E2) and progesterone (P4), as well as to understand their temporal relationships during oestrus in mithun (Bos frontalis). The experiment was conducted on 11 mithuns during third or fourth postpartum oestrous cycle. Since oestrus onset the jugular vein blood samples were collected every 2 h for 72 and 96 h, respectively from the animals without and with standing heat. The LH, FSH, E2 and P4 concentrations were estimated in plasma. The P4 concentration was fluctuated throughout the oestrus period and the average P4 concentration was found significantly (p<0.05) lower on the day of oestrus onset. The multiple rises in LH and FSH concentrations above the basal level in spike like fashion were observed throughout the oestrus period irrespective of the occurrence of standing heat. A significant (p<0.01) gradual increase in the average daily E2 concentration was observed till day 2 following oestrus onset irrespective of the occurrence of standing heat. A significant (p<0.05) simultaneous increase in LH, FSH and E2 concentrations and a transient increase in P4 concentration at approximately the time of standing heat onset were observed. During investigation a definite temporal coupling between LH and FSH rises was absent throughout the oestrus period. The results suggest that (1) the multiple short-duration low-amplitude LH and FSH surges during oestrus may be crucial for the final maturation of ovulatory follicle and subsequent ovulation in mithun; (2) a differential mechanism for controlling LH and FSH secretions probably exists in mithun.

Ocular sparganosis.

A 50-year-old male attended outpatients department with complaints of irritation, foreign body sensation and mild redness in his right eye. On examination a conjunctival nodule was found with localised inflammation. All investigations were normal. Surgical excision of the nodule was contemplated. During local dressing a live tapeworm about 20 cm in length and 3 mm in breadth emerged. Pathological examination confirmed it to be a tapeworm spirometra. The case was diagnosed to be ocular sparganosis.

Validation of a 13,14-dihydro-15-keto-PGF(2alpha) enzymeimmunoassay and its application for reproductive health monitoring in postpartum buffaloes.

The objective of the present study was to validate a simple, sensitive and direct enzymeimmunoassay (EIA) procedure for 13,14-dihydro-15-keto-PGF(2alpha) (PGFM) for use in buffaloes with postpartum reproductive disorders and determine the practicalities of using plasma concentrations of 13,14-dihydro-15-keto-PGF(2alpha) for monitoring their reproductive health. The EIA was used for determination of the circulating levels of PGFM associated with the retention of fetal membranes, postpartum endometritis and variable postpartum intervals. The concentrations of PGFM with retention of fetal membranes in the periparturient period were lower as compared to buffaloes that had uneventful parturitions. Concentrations of PGFM associated with postpartum endometritis were elevated as compared to those in buffaloes free of reproductive tract infections. Buffaloes having higher plasma concentrations of PGFM in early postpartum period had shorter postpartum intervals, indicating the association between PGFM concentrations postpartum and uterine involution as well as the resumption of estrous cycle in this species. The study presents the possibility of using circulating PGFM concentrations for monitoring the postpartum reproductive health of buffaloes.

Endocrine control of estrous cycle in mithun (Bos frontalis).

The objective of the present study was to establish the profiles of luteinising hormone (LH), follicle stimulating hormone (FSH), estradiol 17beta (E2) and progesterone (P4) secretion and their interrelationships during the natural estrous cycle of mithun (Bos frontalis). Daily blood samples were collected from second or third postpartum estrous cycles for determination of plasma concentrations of LH, FSH, E2 and P4. Concentration of P4 was found to be lowest on the day of estrus. It increased following estrus, attained the highest concentration on day 11 and decreased thereafter. Concentrations of LH and FSH varied significantly (p<0.01) during the first and last 6 days of the cycle and their variations were found to be synchronised. Both LH and FSH attained a biphasic peak during the estrous cycle. This biphasic peak lasted on from day -5 to day 3 of the cycle. The variations in maximum LH and FSH concentrations of both the phases did not differ significantly. During the entire estrous cycle, the E2 concentrations attained either one peak or two peaks. The first peak, approximately on day 4 before estrus was common in all animals. One additional peak was found on the day of estrus in 45% animals. A significant (p<0.01) negative relationship was found between P4 and, LH and FSH during the first and last 6 days of cycle. But a significant (p

Immuno-pathotyping of Karnal bunt (Tilletia indica) isolates of wheat using anti-mycelial antibodies.

Two types of polyclonal antibodies raised against whole lyophilized (LMA) and fractionated mycelial antigen (FMA) of most virulent, Pantnagar isolate of T. indica were used for the development of immunoassay systems, viz. dot immuno-binding assay (DIBA) and indirect enzyme linked immuno-sorbent assay (ELISA) procedures. The immuno-assays were developed by performing antigen concentration kinetics and antibody dilution curves analyses. These assays were employed for immuno-analysis of diversity amongst KB pathogen based on antibodies reactivity pattern and subsequently categorization into distinct sero-groups. The reactivity of two polyclonal antibodies was tested with 15 (P1-P15) isolates of T. indica. When anti-LMA antibodies were tested, four serologically distinct groups were formed based on percent reactivity (>75%, highly reactive; 60-75%; moderately reactive, <50-25%; low reactive and <25%, non-reactive). However, when anti-FMA antibodies were used, two distinct sero-groups were formed based on reactivity patterns (group I, highly reactive P1, P3, P4, P11 and P13, group II, less reactive P2, P4, P5, P6, P7, P8, P9, P10, P12, P14 and P15).

Atypical manifestations of Plasmodium vivax malaria.

About 110 patients were enrolled to study the atypical presentations and the chloroquine sensitivity pattern of Plasmodium vivax malaria. The diagnosis was made from Giemsa stained peripheral blood smear. The co-infection of falciparum malaria was excluded both by smear and ParaSight F-test. After a thorough clinical work up, biochemical investigations were done. The fever clearance and parasite clearance time were determined in all cases. Absence of malarial paroxysm (22.8 per cent), migrainous headache (4.5 per cent), myalgia (6.3 per cent), episodic urticarial rash (1.8 per cent), relative bradycardia (13.6 per cent) and postural hypotension (2.7 per cent) were the atypical manifestations encountered. Besides this, severe forms like jaundice (7.2 per cent), cerebral involvement (0.9 per cent), severe anaemia (7.2 per cent), thrombocytopenia (3.6 per cent) and pancytopenia (0.9 per cent) had been detected. All, except the patient with cerebral involvement were treated with chloroquine patients responded well to the treatment except two (1.8 per cent) patients who had chloroquine resistance. This study showed that vivax malaria can present with atypical and protean manifestations. The changing clinical profile along with development of chloroquine resistance may be considered as a warning signal.

Isolation, partial characterization and growth characteristics of a bacterium resistant to aflatoxin B1.

A bacterium was isolated from the soil of dumping ground for cattle yard waste by enrichment culture containing aflatoxin B1. This bacterium was closely related to Bacillus firmus that was found to be a non-pathogenic bacterium. The minimum inhibitory concentration of aflatoxin B1 to the bacterium was found to be 80 microg ml(-1) as measured by total viable count and soluble protein content methods. The bacterium was sensitive to all the tested antibiotics. Plasmid curing by chemical agents did not show the resistance character residing in the plasmid. Protein profiles of cell extracts of aflatoxin B1 resistant bacterium grown in the presence and absence of the toxin showed 46 and 44 protein bands respectively in SDS-PAGE. It was observed that 39 bands were common in both the extracts and the remaining bands were showing differences near the high molecular weight range.

Mechanism of removal of aflatoxin B1 by a resistant bacterium.

A bacterium resistant to aflatoxin B1 isolated from the soil was shown to remove a maximum 26% of toxin at 3 microg ml(-1). A comparison of spectrophotometric and radioisotope methods showed that a maximum of 48 hr was sufficient to remove the toxin. Radioisotope analysis showed that the radioactivity decreased in the chloroform phase while it increased in the aqueous phase during the time course of the experiment. An analysis of the supernatant of culture medium showed that the bacterium had converted aflatoxin B1 to water soluble compounds with lambda(max) of 338 and 374.

Total quality management in health services: historical development, conceptual meaning, and comprehensive model.

Today's health care environment is characterized by burgeoning costs and increasing concern about service quality. Not surprisingly, researchers and practitioners are turning to Total Quality Management (TQM) in their quest for creating high quality health care delivery systems. Despite the central importance of TQM, there is practically no common definition of total quality in medical care research. In this paper, we trace the historical development of the quality concept, offer a valid definition of "total quality," and detail a comprehensive model of TQM for health care research. Implications of our model for academicians and practitioners are discussed.